LSANE
ActiveSummary
LSANE has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €19,297 and a net result of €284,268. Equity is shrinking by about 30% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 10% of 20,659 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Activity
Specialist medical practice
NACE 86220
1 site
Size
≈ €590,000turnover 2025, estimated
- Equity
- €19,297
- Profit
- €284,268
Turnover estimated from the gross margin
Structure
2025 accounts 7 days early2 of 4 deeds summarised
Why 93raises risk1 change of registered office in 24 monthsEquity €19,297 (4.4% of total assets)lowers riskSector: Human health activities (NACE 86)Figures for financial year 2025 (filed 24-07-2026)Show the evidence
Checked score
Score 2025
93
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 52% of its sector peers (NACE 86, micro)
Financial strength · tick = 2024
Strong
Solvency
29+3
equity 4.4% of total assets
Liquidity
50=
short-term debt 95.6% · cash 52.2%
Profitability
100=
return on assets 64.1%
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: < 0.1%lowest value
12-2024: < 0.1%● unchanged vs 11-2024lowest value
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026highest value
10-2026: 0.1%● unchanged vs 09-2026highest value
Credit of up to €1,500 on 30-day terms is acceptable
Liquidity tight (current ratio 1.04, compared with 1.01 in 2024, below the usual 1.5; short-term debt: 95.6% and cash: 52.2% of total assets), and 95.6% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 10% on solvency, 20% on liquidity, 80% on profitability and 96% on growth.
The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 20659 sector peers (2025).
NBB · sector comparisonPosition among 20659 sector peers
Solvency
better than 10%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-07-2026, 7 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
7 days early
2024
28 days early
2023
7 days early
2022
10 days early
2021
13 days early
2020
15 days early
2019
14 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 13 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 21 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
31-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · micro…
- Registered officeRegistered-office move
- Annual accounts filedfinancial year 2024 · micro…
Financials · financial year 2025, micro format
Turnover
≈ €590,000
Estimated: probably between €530,000 and €740,000
Total assets
€443,488▲ 31.0%
2024 · €338,627
Net result
€284,268▼ 2.7%
2024 · €292,270
Working capital
€15,325▲ 341%
2024 · €3,477
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 3% below 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result€374,818
2025
Net result€284,268
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€443,488
2025
Equity€19,297
2025
Debt€424,191
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€15,325
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)64.1%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency4.4%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.04
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€284,329-€317,876▲ 11.8%€331,942▲ 4.4%€326,215▼ 1.7%€290,760▼ 10.9%€339,796▲ 16.9%€387,441▲ 14.0%€374,818▼ 3.3%
Net result€205,329-€229,215▲ 11.6%€254,074above the sector's middle half▲ 10.8%€242,476within the sector's middle half▼ 4.6%€222,007within the sector's middle half▼ 8.4%€262,106within the sector's middle half▲ 18.1%€292,270above the sector's middle half▲ 11.5%€284,268above the sector's middle half▼ 2.7%
Equity€156,601-€160,816▲ 2.7%€159,890within the sector's middle half▼ 0.6%€84,226below the sector's middle half▼ 47.3%€84,233below the sector's middle half=€23,160below the sector's middle half▼ 72.5%€5,030below the sector's middle half▼ 78.3%€19,297below the sector's middle half▲ 284%
Total assets€472,863-€419,425▼ 11.3%€561,950within the sector's middle half▲ 34.0%€571,544within the sector's middle half▲ 1.7%€592,048within the sector's middle half▲ 3.6%€438,632below the sector's middle half▼ 25.9%€338,627within the sector's middle half▼ 22.8%€443,488within the sector's middle half▲ 31.0%
Debt€316,262-€258,610▼ 18.2%€402,060▲ 55.5%€487,318▲ 21.2%€507,815▲ 4.2%€415,472▼ 18.2%€333,597▼ 19.7%€424,191▲ 27.2%
Working capital€156,592-€151,761▼ 3.1%€136,392within the sector's middle half▼ 10.1%€71,903within the sector's middle half▼ 47.3%€78,823within the sector's middle half▲ 9.6%€20,273below the sector's middle half▼ 74.3%€3,477below the sector's middle half▼ 82.9%€15,325within the sector's middle half▲ 341%
Solvency33.1%-38.3%▲ 5.2pp28.5%below the sector's middle half▼ 9.9pp14.7%below the sector's middle half▼ 13.7pp14.2%below the sector's middle half▼ 0.5pp5.3%below the sector's middle half▼ 8.9pp1.5%below the sector's middle half▼ 3.8pp4.4%below the sector's middle half▲ 2.9pp
Current ratio1.51-1.59▲ 0.081.34below the sector's middle half▼ 0.251.15below the sector's middle half▼ 0.191.16below the sector's middle half▲ 0.011.05below the sector's middle half▼ 0.111.01below the sector's middle half▼ 0.041.04below the sector's middle half▲ 0.03
Return on assets (ROA)43.4%-54.6%▲ 11.2pp45.2%above the sector's middle half▼ 9.4pp42.4%above the sector's middle half▼ 2.8pp37.5%above the sector's middle half▼ 4.9pp59.8%above the sector's middle half▲ 22.3pp86.3%above the sector's middle half▲ 26.6pp64.1%above the sector's middle half▼ 22.2pp
above
within
below
the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €443,488
Fixed assets
€3,973 ▲ 156%
Current assets
€439,515 ▲ 30.4%
Equity and liabilities €443,488
Equity
€19,297 ▲ 284%
Debt
€424,191 ▲ 27.2%
Debt's share of the balance-sheet total falls from 98.5% to 95.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€377,320▼
2024 · €388,775
Cash flow
€286,769▼
2024 · €293,604
Debt to equity
21.98▼
2024 · 66.33
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€424,191▲
2024 · €333,597
Income taxes
€90,646▼
2024 · €95,174
A ratio outside any meaningful range has been withheld (balance sheet total €443,488, equity €19,297).
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 1,325 companies that looked in July 2024 the way this one looks now, 1.4% went bankrupt within 24 months and 95.2% are still going.
- Micro
- 10 to 20 years old
- solvency under 10%
- a profit of 5% of the balance sheet or more
1.4%
went bankrupt
3.2%
stopped otherwise
95.2%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 1,325 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | €18,777 | - | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €6,242 | €11,155 | €5,669 | €17,408 | €6,913 | €6,197 | €1,334 | €2,502 | ▲ 87.5% |
| Other operating charges640/8 | - | - | - | €2,112 | €5,308 | €2,075 | €1,929 | €1,990 | ▲ 3.2% |
| Gross operating margin9900 | €293,725 | €330,643 | €339,570 | €345,735 | €302,982 | €348,068 | €390,704 | €379,310 | ▼ 2.9% |
| Operating profit (loss)9901 | €284,329 | €317,876 | €331,942 | €326,215 | €290,760 | €339,796 | €387,441 | €374,818 | ▼ 3.3% |
| Financial income75/76B | - | - | - | €1,750 | €1,750 | €2,839 | €1,399 | €955 | ▼ 31.7% |
| Recurring financial income75 | €0 | €438 | €1,750 | €1,750 | €1,750 | €2,839 | €1,399 | €955 | ▼ 31.7% |
| Financial charges65/66B | - | - | - | €1,587 | €366 | €1,403 | €1,397 | €860 | ▼ 38.5% |
| Recurring financial charges65 | €1,800 | €1,799 | €269 | €1,587 | €366 | €1,403 | €1,397 | €860 | ▼ 38.5% |
| Profit (loss) for the period before taxes9903 | €282,528 | €316,514 | €333,423 | €326,378 | €292,144 | €341,232 | €387,443 | €374,914 | ▼ 3.2% |
| Income taxes67/77 | €77,199 | €87,300 | €79,348 | €83,902 | €70,138 | €79,126 | €95,174 | €90,646 | ▼ 4.8% |
| Profit (loss) for the period9904 | €205,329 | €229,215 | €254,074 | €242,476 | €222,007 | €262,106 | €292,270 | €284,268 | ▼ 2.7% |
| Transfer from tax-exempt reserves789 | - | - | - | €16,050 | - | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €205,329 | €229,215 | €254,074 | €258,526 | €222,007 | €262,106 | €292,270 | €284,268 | ▼ 2.7% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €472,863 | €419,425 | €561,950 | €571,544 | €592,048 | €438,632 | €338,627 | €443,488 | ▲ 31.0% |
| Fixed assets21/28 | €11,330 | €12,116 | €23,497 | €12,323 | €5,410 | €2,887 | €1,553 | €3,973 | ▲ 156% |
| Tangible fixed assets22/27 | €11,330 | €12,116 | €23,497 | €12,323 | €5,410 | €2,887 | €1,553 | €3,973 | ▲ 156% |
| Plant, machinery and equipment23 | - | - | - | €11,188 | €4,842 | €2,887 | €1,553 | €541 | ▼ 65.2% |
| Furniture and vehicles24 | - | - | - | €1,135 | €568 | - | - | €3,432 | - |
| Current assets29/58 | €461,533 | €407,309 | €538,453 | €559,221 | €586,638 | €435,745 | €337,074 | €439,515 | ▲ 30.4% |
| Amounts receivable after more than one year29 | - | - | - | €175,000 | €175,000 | - | - | - | - |
| Other amounts receivable291 | - | - | - | €175,000 | €175,000 | - | - | - | - |
| Amounts receivable within one year40/41 | - | €3,438 | €7,699 | €603 | €22,188 | - | - | €20,000 | - |
| Trade receivables40 | - | - | - | €166 | - | - | - | - | - |
| Other amounts receivable41 | - | - | - | €438 | €22,188 | - | - | €20,000 | - |
| Cash at bank and in hand54/58 | €269,600 | €22,829 | €152,792 | €219,335 | €205,092 | €253,418 | €148,934 | €231,682 | ▲ 55.6% |
| Deferred charges and accrued income490/1 | - | - | - | €164,283 | €184,359 | €182,327 | €188,140 | €187,833 | ▼ 0.2% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €472,863 | €419,425 | €561,950 | €571,544 | €592,048 | €438,632 | €338,627 | €443,488 | ▲ 31.0% |
| Equity10/15 | €156,601 | €160,816 | €159,890 | €84,226 | €84,233 | €23,160 | €5,030 | €19,297 | ▲ 284% |
| Contributions10/11 | €18,600 | €18,600 | - | €18,600 | €18,600 | €18,600 | €60 | €60 | = |
| Reserves13 | €136,750 | €136,750 | €136,750 | €52,560 | €52,560 | €4,560 | €2,700 | €2,700 | = |
| Non-distributable reserves130/1 | - | - | - | €1,860 | €1,860 | €1,860 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €1,860 | €1,860 | €1,860 | - | - | - |
| Tax-exempt reserves132 | - | - | - | €2,700 | €2,700 | €2,700 | €2,700 | €2,700 | = |
| Distributable reserves133 | - | - | - | €48,000 | €48,000 | - | - | - | - |
| Profit (loss) carried forward14 | €1,251 | €5,466 | €4,540 | €13,066 | €13,073 | - | €2,270 | €16,537 | ▲ 629% |
| Amounts payable17/49 | €316,262 | €258,610 | €402,060 | €487,318 | €507,815 | €415,472 | €333,597 | €424,191 | ▲ 27.2% |
| Amounts payable after more than one year17 | €1,697 | - | - | - | - | - | - | - | - |
| Amounts payable within one year42/48 | €304,942 | €255,547 | €402,060 | €487,318 | €507,815 | €415,472 | €333,597 | €424,191 | ▲ 27.2% |
| Trade debts44 | €24,334 | €3,701 | €3,360 | €3,171 | €8,026 | €2,958 | €3,749 | €1,815 | ▼ 51.6% |
| Suppliers440/4 | - | - | - | €3,171 | €8,026 | €2,958 | €3,749 | €1,815 | ▼ 51.6% |
| Taxes, remuneration and social security45 | - | - | - | €6,638 | €8,438 | €12,248 | €13,300 | €43,800 | ▲ 229% |
| Taxes450/3 | - | - | - | €6,638 | €8,438 | €12,248 | €13,300 | €43,800 | ▲ 229% |
| Other amounts payable47/48 | - | - | - | €477,509 | €491,352 | €400,266 | €316,548 | €378,576 | ▲ 19.6% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €205,329 | €229,215 | €254,074 | €242,476 | €222,007 | €262,106 | €292,270 | €284,268 | ▼ 2.7% |
| + Depreciation and write-downs630 | €6,242 | €11,155 | €5,669 | €17,408 | €6,913 | €6,197 | €1,334 | €2,502 | ▲ 87.5% |
| Operating cash flow (approximation) | €211,571 | €240,369 | €259,743 | €259,884 | €228,920 | €268,303 | €293,604 | €286,769 | ▼ 2.3% |
| Investment in fixed assets (approximation) | - | -€11,941 | -€17,050 | -€6,234 | €0 | -€3,674 | €0 | -€4,921 | - |
| Change in cash | - | -€246,771 | €129,964 | €66,543 | -€14,243 | €48,326 | -€104,484 | €82,748 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 11 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 24-07-2026 | 2026-00327179 |
| 31-12-2024 | micro format | 03-07-2025 | 2025-00222737 |
| 31-12-2023 | abbreviated format | 24-07-2024 | 2024-00275837 |
| 31-12-2022 | abbreviated format | 21-07-2023 | 2023-00258026 |
| 31-12-2021 | abbreviated format | 18-07-2022 | 2022-20195704 |
| 31-12-2020 | abbreviated format | 16-07-2021 | 2021-36300337 |
| 31-12-2019 | abbreviated format | 17-07-2020 | 2020-31300341 |
| 31-12-2018 | abbreviated format | 18-07-2019 | 2019-34400200 |
| 31-12-2017 | abbreviated format | 19-07-2018 | 2018-35500172 |
| 31-12-2016 | abbreviated format | 08-07-2017 | 2017-29400570 |
Similar companies · same sector, comparable size
DR. CHRISTOPHE LEBRUN
BE 0628.895.045
Oud-Turnhout · equity €19,292
Dr. Leen Sinnaeve
BE 0716.679.748
Oostkamp · equity €19,336
DOKTER JOKE YSENBAERT
BE 0697.728.621
Roeselare · equity €19,337
M-PIBOX
BE 0761.469.992
Trooz · equity €19,341
NEFROLOGIE IEPER
BE 0724.846.158
Ieper · equity €19,350
Of the 16,577 active companies whose main activity is specialist medical practice (NACE 86220), figures are known for 8,127. 3,328 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
no sitting director read yet, last change in 2024
No directors read yet: 2 of 4 Gazette acts processed. See the directors and other office holders in the KBO →
Mandate history
1 person since 2023, 0 in office
- Board
| Name | Functions and periods |
|---|---|
| Stoffel LAMOTE |
|
Owners and capital
Capital and shareholders
Capital over the years
- 25-01-2024 Converted to unavailable equity
Group and network
Connections & network
No directors read yet: 2 of 4 Gazette acts processed.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
24-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
13-07
Gazette deed
Registered officeRegistered-office move2 facts ▸
Gazette deed
Registered office
Registered-office move2 facts ▸
- General meeting, 06-05-2026
- Registered-office move, Beverlaai(Kor) 11a, 8500 Kortrijk
2025
03-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-12
Financial
Highest result from 2018 to 2025net €292,270 ▲11.5%
Operating result €387,441, net result €292,270, both a record.
24-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
25-01
Gazette deed
Resignation: Stoffel LAMOTE (manager)Appointment: Stoffel LAMOTE (statutory director) · Amendment of the articles · Capital conversion17 facts ▸
Gazette deed
Resignation: Stoffel LAMOTE (manager)
Appointment: Stoffel LAMOTE (statutory director) · Amendment of the articles · Capital conversion17 facts ▸
- Other provision, 05-01-2024
- General meeting, 22-12-2023
- Amendment of the articles (3 times)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “vormen en meerderheden van de statutenwijziging, statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Name change, LSANE
- Registered office clause, “Vlaamse Gewest, Don Boscolaan 28,8500 Kortrijk” (deed in Dutch)
- Other provision, “kennisname mogelijkheid om website of e-mailadres op te nemen op de KBO, website en e-mailadres op KBO” (deed in Dutch)
- Director resignation, Stoffel LAMOTE (manager)
- Director appointment, Stoffel LAMOTE (statutory director)
- Board composition, Stoffel LAMOTE (director)
- Other provision, “verbodsbepaling voor uitoefening mandaat, niet getroffen” (deed in Dutch)
- +5 further facts in this act
2023
21-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
18-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
16-07
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
17-07
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
18-07
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
19-07
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
08-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 11 annual accounts filed, the latest 10 are here; all 11 are under Financials.
2 of 4 deeds read
About the unread acts
Of the 4 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Register details
Identification
Legal formPrivate limited company
Founded28-09-2015
Financial year end31-12
Activities, NACEBEL 2025
86220Specialist medical practice
E-invoicing
Reachable via Peppol
Peppol ID
0208:0638889609
Also
9925:BE0638889609
Registered
19-11-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 31 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Kortrijk · 1 establishment unit since 2015
Ground area
3,071 m²
Building footprint
445 m²
Building volume
1,205 m³
2 parcels, Flanders · tallest building 8.9 m. Linked by address, not a title deed.
1 establishment unit
LAMOTE STOFFEL DR. anesthesie
since 2015unit no. 2.246.382.616
2 parcels
Flanders
2
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 34022E1024/00H000 | Flanders | 1,822 m² | 1 · 208 m² | 8.9 m · 2 |
| 34022E0091/00V005 | Flanders | 1,249 m² | 1 · 237 m² | - |
How the parcels are linked
Good to know
Both parcels match the address exactly.
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “Het uitoefenen van de geneeskunde op het gebied van anesthesie, door het organiseren, bevorderen en structureren van alle…” (deed in Dutch)
8 activities (deed in Dutch)
- Het uitoefenen van de geneeskunde op het gebied van anesthesie, door het organiseren, bevorderen en structureren van alle beroepsactiviteiten van de arts-aandeelhouder of artsen-aandeelhouders; dit in al zijn facetten en rekening houdend met de regelen van de Medische Plichtenleer qua uitoefening van de geneeskunde. De geneeskunde wordt evenwel enkel uitgeoefend door de arts-aandeelhouder of artsen-aandeelhouders, die voor de geneeskundige prestaties persoonlijk instaa(t)(n) en dit in naam en voor rekening van de vennootschap, en geenszins door de vennootschap zelf;
- Het zetelen in commissies en organen waar het wettelijk diploma van arts of een bijzondere beroepstitel vereist is;
- Het ter beschikking stellen van de nodige middelen voor de arts-aandeelhouder(s);
- Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder die nuttig of nodig zijn voor de uitoefening van voormelde activiteit;
- Het verwerven, het huren en/of leasen van alle medische apparatuur en begeleidende accommodaties, inclusief gebouwen en transportmiddelen, kortom van een volledige materiële infrastructuur, om deze ter beschikking te stellen van de arts-aandeelhouder(s);
- Het aanleggen van reserves, nodig tot het aanschaffen van alle dienstige apparatuur, gebouwen en transportmiddelen noodzakelijk en bevorderlijk voor het uitoefenen van alle bovenvermelde beroepsactiviteiten door de arts-aandeelhouder(s);
- Het scheppen van de mogelijkheden om de arts-aandeelhouder(s) toe te laten zich verder te bekwamen in voormelde medische discipline, dit teneinde een kwalitatief hoogstaande praktijkuitoefening mogelijk te maken;
- Het verstrekken van informatie, het organiseren van seminaries, colloquia, cursussen, studiereizen en lessencycli in verband met voormelde beroepsactiviteit; zonder dat dit de vorm van een aanvullende commerciële activiteit mag aannemen.
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- LSANE
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Bestuursorgaan, een of meer bestuurders” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Saturday of June at 19:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Algemene vergadering in vormen vereist voor statutenwijziging, beroep op artsen voor persoonlijke levenssfeer patiënten en/of beroepsgeheim…” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Bestuurder(s) in functie als vereffenaar(s) indien geen andere vereffenaar benoemd, beroep op artsen voor persoonlijke levenssfeer patiënten…” (deed in Dutch)